Introduction: Adequate methods to promptly translate digital health innovations for improved patient care are essential. Advances in Artificial Intelligence (AI) and Machine Learning (ML) have been sources of digital innovation and hold the promise to revolutionize the way we treat, manage and diagnose patients. Understanding the benefits but also the potential adverse effects of digital health innovations, particularly when these are made available or applied on healthier segments of the population is essential. One of such adverse effects is overdiagnosis.
Objective: to comprehensively analyze quantification strategies and data-driven definitions for overdiagnosis reported in the literature.
Methods: we conducted a scoping systematic review of manuscripts describing quantitative methods to estimate the proportion of overdiagnosed patients.
Results: we identified 46 studies that met our inclusion criteria. They covered a variety of clinical conditions, primarily breast and prostate cancer. Methods to quantify overdiagnosis included both prospective and retrospective methods including randomized clinical trials, and simulations.
Conclusion: a variety of methods to quantify overdiagnosis have been published, producing widely diverging results. A standard method to quantify overdiagnosis is needed to allow its mitigation during the rapidly increasing development of new digital diagnostic tools.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jbi.2023.104506 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Quantifying Overdiagnosis for Multicancer Detection Tests: A Novel Method.
Stat Med
December 2024
Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA.
Multicancer detection (MCD) tests use blood specimens to detect preclinical cancers. A major concern is overdiagnosis, the detection of preclinical cancer on screening that would not have developed into symptomatic cancer in the absence of screening. Because overdiagnosis can lead to unnecessary and harmful treatments, its quantification is important.
View Article and Find Full Text PDFClustering of clinical symptoms using large language models reveals low diagnostic specificity of proposed alternatives to consensus mast cell activation syndrome criteria.
J Allergy Clin Immunol
September 2024
Institute for Immunity, Transplantation, and Infection, School of Medicine, Stanford University, Palo Alto, Calif; Department of Medicine, Center for Biomedical Informatics Research, School of Medicine, Stanford University, Palo Alto, Calif.
Article Synopsis
- - The diagnosis of mast cell activation syndrome (MCAS) has risen, but while there are established consortium criteria, there are also alternative criteria that may not be as specific.
- - Researchers used advanced language models to analyze diagnostic probabilities and found that alternative criteria led to broader and less precise diagnoses compared to the consortium criteria.
- - The study concluded that alternative MCAS criteria result in a diverse range of diagnoses, making them less reliable and potentially leading to misclassifications when compared to established conditions like systemic lupus erythematosus.
Budget impact analysis of introducing digital breast tomosynthesis in breast cancer screening in Italy.
Radiol Med
September 2024
Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Purpose: This study quantifies the impact on budget and cost per health benefit of implementing digital breast tomosynthesis (DBT) in place of digital mammography (DM) for breast cancer screening among asymptomatic women in Italy.
Methods: A budget impact analysis and a cost consequence analysis were conducted using parameters from the MAITA project and literature. The study considered four scenarios for DBT implementation, i.
Estimating the magnitude and healthcare costs of melanoma in situ and thin invasive melanoma overdiagnosis in Australia.
Br J Dermatol
November 2024
Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Background: Research suggests that a high proportion of melanoma in situ (MIS) may be overdiagnosed, potentially contributing to overtreatment, patient harm and inflated costs for individuals and healthcare systems. However, Australia-wide estimates of the magnitude of melanoma overdiagnosis are potentially outdated and there has been no estimation of the cost to the healthcare system.
Objectives: To estimate the magnitude and cost of overdiagnosed MIS and thin invasive melanomas in Australia.
Evaluating gender bias in ML-based clinical risk prediction models: A study on multiple use cases at different hospitals.
J Biomed Inform
September 2024
Dedalus Healthcare, Antwerp, Belgium.
Background: An inherent difference exists between male and female bodies, the historical under-representation of females in clinical trials widened this gap in existing healthcare data. The fairness of clinical decision-support tools is at risk when developed based on biased data. This paper aims to quantitatively assess the gender bias in risk prediction models.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!